Bayer announced the FDA has approved Kerendia (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death,… read more.
The European Medicine Agency’s key decision-making committee on human medicines (CHMP), has recommended eight medicines for approval at its June meeting. The Committee recommended granting a conditional marketing authorisation for Abecma… read more.
Hansa Biopharma, announced three-year follow-up data in crossmatch positive patients who received imlifidase prior to kidney transplantation. As reported in an article, which has been accepted for publication… read more.
AstraZeneca’s Forxiga (dapagliflozin) has been recommended for approval in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes… read more.
Article by Bruce Sylvester. Investigative tirzepatide appears to improve glycaemic control and bodyweight in Type 2 diabetes patients, without raising the risk of hypoglycemia. Researchers reported these findings… read more.
The European Commission has granted marketing authorization for Jardiance (empagliflozin) as a treatment for adults with symptomatic chronic heart failure with reduced ejection fraction (systolic heart failure), Boehringer… read more.
Immunotherapy with pembrolizumab after surgery significantly improves disease-free survival among patients with the most prevalent form of kidney cancer, clear-cell renal carcinoma. Researchers reported this finding on June… read more.
Interview and article by Christine Clark. Dr Suryakant (Head of the Department of Respiratory Medicine at King George Medical University in Lucknow, India) explains how an ivermectin-based therapy… read more.
Article written by Gary Finnegan. Chronic kidney disease affects approximately 700 million people worldwide with many going on to require dialysis. Now a new enzyme has been discovered… read more.
GlaxoSmithKline plc announced the European Commission has approved the expanded use of intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult… read more.
Health Canada has approved daratumumab injection (Darzalex SC), a subcutaneous formulation of daratumumab (Darzalex), for use in combination with bortezomib, cyclophosphamide, and dexamethasone (D-VCd; VCd) in the treatment… read more.
AstraZeneca’s Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
